Atrial Natriuretic Peptide (ANP)
Evidence: CCardiovascular / Vascular
Evidence Snapshot
Regulatory Context
No molecule-wide regulatory conclusion is verified for all ANP preparations. This page summarizes research on the peptide and does not imply that the peptide is an FDA-approved drug or approved for a particular indication.
Research Takeaway
Atrial Natriuretic Peptide (ANP), also historically termed Atrial Natriuretic Factor (ANF), is a mature cardiac natriuretic peptide distinct from proANP/preproANP products, urodilatin, BNP, and CNP.
Evidence boundary: Shared natriuretic-peptide family signaling does not make precursor fragments or sibling natriuretic peptides interchangeable with mature ANP.
See all 6 evidence claims →Quick Summary
Atrial Natriuretic Peptide (ANP) is a mature cardiac natriuretic peptide with direct human vascular and hemodynamic evidence. Recombinant human ANP has also been studied in randomized clinical settings, but product-specific treatment evidence should remain distinct from the broader physiology of endogenous ANP.
Mechanism & Research Overview
Atrial Natriuretic Peptide (ANP) is a mature cardiac natriuretic peptide with direct human vascular and hemodynamic evidence. Recombinant human ANP has also been studied in randomized clinical settings, but product-specific treatment evidence should remain distinct from the broader physiology of endogenous ANP.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Atrial Natriuretic Peptide (ANP), also historically termed Atrial Natriuretic Factor (ANF), is a mature cardiac natriuretic peptide distinct from proANP/preproANP products, urodilatin, BNP, and CNP.
Does not establish
Evidence boundary: Shared natriuretic-peptide family signaling does not make precursor fragments or sibling natriuretic peptides interchangeable with mature ANP.
Sources: Hemodynamic effects of alpha-human atrial natriuretic peptide in healthy volunteers; Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man
Supported
Direct administration of mature human ANP in controlled human studies produces measurable acute vascular and hemodynamic effects.
Does not establish
Evidence boundary: These findings describe acute human pharmacology, not durable therapeutic efficacy.
Sources: Hemodynamic effects of alpha-human atrial natriuretic peptide in healthy volunteers; Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man; Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers
Supported
Recombinant human ANP has also been tested in randomized clinical studies in acute renal failure and acute decompensated heart failure.
Does not establish
Evidence boundary: These are recombinant-product clinical studies and should not be rewritten as proof that every native or compounded ANP preparation has the same clinical efficacy, safety, or dosing profile.
Sources: Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial; Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
Supported
ANP has a meaningful direct-human evidence base, but much of the higher-level treatment literature involves recombinant human ANP products rather than endogenous peptide physiology alone.
Sources: Hemodynamic effects of alpha-human atrial natriuretic peptide in healthy volunteers; Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial; Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
Supported
Human ANP studies demonstrate that clinically relevant hemodynamic and renal effects can occur during administration.
Does not establish
Evidence boundary: Short-term infusion trials do not define long-term safety for chronic or unsupervised use.
Sources: Hemodynamic effects of alpha-human atrial natriuretic peptide in healthy volunteers; Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man; Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial; Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
Supported
No molecule-wide regulatory conclusion for all ANP preparations is frozen in Stage 2B.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
ANP is vasoactive and can alter arterial pressure, vascular tone, renal handling, and volume-regulatory physiology.Safety Consideration
Recombinant-product clinical findings do not establish long-term safety for arbitrary native or compounded ANP exposure.Safety Consideration
Mature ANP must not be confused with precursor fragments, urodilatin, BNP, or CNP.
Research Areas Being Studied
Research areas discussed on this page reflect the Cardiovascular / Vascular category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (2016):
- Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers (2015):
- Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial (2004):
- Hemodynamic effects of alpha-human atrial natriuretic peptide in healthy volunteers (1988):
- Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man (1987):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial | 2016 | Acute decompensated heart failure; multicenter randomized double-blind placebo-controlled phase III | Recombinant human ANP was tested as a short infusion in acute decompensated heart failure. | ||
| Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers | 2015 | Six healthy volunteers; double-blind three-way (or three-day) crossover comparing ANP, BNP, and CNP | Directly compared cerebral/systemic vascular responses to three natriuretic peptides (ANP, BNP, CNP) on separate study days/arms. | ||
| Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial | 2004 | Ischemic acute renal failure; randomized placebo-controlled | Randomized trial tested recombinant human ANP in acute renal failure. | ||
| Hemodynamic effects of alpha-human atrial natriuretic peptide in healthy volunteers | 1988 | Healthy human volunteers | Direct alpha-hANP administration produced measurable acute hemodynamic effects in healthy volunteers. | ||
| Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man | 1987 | Healthy humans | Human ANP produced vasodilator/hemodynamic effects in normal participants. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-25.
Follow research updates for Atrial Natriuretic Peptide (ANP)
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.